Skip to content
PeptidePlotter logo PeptidePlotter
Search (no-JS fallback)

Peptides

Survodutide

Also called Survodu · BI 456906

Survodutide is an investigational drug being studied for weight loss and fatty liver disease. Its appeal is a GLP-1-plus-glucagon approach that may address both appetite and metabolism; comparisons with tirzepatide or retatrutide still need treatment-specific evidence.

Open the plotter Sources

Dosage & duration

Phase 2 obesity study in adults without diabetes; research context.

Obesity trial target-dose groups

Published example · product-specific
Dose
0.6, 2.4, 3.6 or 4.8 mg
How often
Once weekly, under the skin
How long
46 weeks

20 weeks of dose escalation followed by 26 weeks of maintenance; these are separate trial groups, not starting doses.

Sources: 1

A clinical trial schedule is not a self-directed product instruction.

More quick facts
Why people look it up
Weight plus liver fat
Sources : 1 · 2
Drug approach
GLP-1 and glucagon
Sources : 1 · 2
Time scale
Months of treatment
Sources : 1 · 2

Two research goals

Body weight and liver fat answer different questions

  • Body weight

    Obesity studies ask how much weight changes during treatment.

  • Liver fat

    Studies in people with fatty liver assess fat stored in the liver.

  • Stomach tolerability

    Digestive effects can affect whether participants stay on treatment.

Less liver fat does not establish reversal of every form of liver disease. Sources and context
In this guide

Why it attracts attention

People comparing newer weight-loss drugs want to know whether survodutide offers something beyond appetite control. Its research includes both obesity and metabolic fatty liver disease, so the liver story is a real clinical question rather than simply a “fat burner” claim.

Weight loss and liver results answer different questions

The obesity trial measured weight over 46 weeks. A later phase 3 study in people with obesity and fatty liver assessed liver fat and weight at 48 weeks. Less liver fat is not the same as proving that every kind of liver scarring or advanced disease is reversed.

What to expect from the dose figures

Trial doses were reached through gradual escalation. Stomach tolerability and remaining on treatment affect the results; a target-dose result does not mean taking that amount immediately. Cross-trial percentages do not establish which drug would work best for an individual.

Model details: Survodutide · estimated

How to read this estimate

Estimated from study endpoints; the curve between measurements is reconstructed. Compare amounts and timing in mg.

A concentration estimate reconstructed from the stated source dose and timing.

Assumptions, calculation and sources

BI4569062mg/mL trial solution SC abdominal-wall injection before breakfast.. subcutaneous. Healthy Japanese men age20–45,BMI23–40; DG2 first-dose Cmax/Tmax n=9,finite AUC n=8;3 completed escalation..

survodutide: estimated concentration in plasma (nmol/L).

Table4 first0.6mg dose Tmax23.7h; Results3.3 reports DG2 terminal half-life114h after repeated/escalated dosing.

Calibration dose
0.6 mg
Reported calibration peak
16.9 nmol/L
Peak timing used
23.7 hours
Terminal half-life used
114 hours
Reconstructed absorption rate
0.1377392 /hour
  • Observed extravascular concentrations already contain bioavailability; do not multiply by legacy F or add an independently assumed F.
  • Dose scaling and repeated-dose superposition use fixed parameters; the example dose does not calibrate the curve.
  • Terminal half-life was estimated after escalation and only in DG2; this rate is assumed unchanged for single-dose reconstruction.
  • At4.8mg, late-trial201nmol/L is a repeated-dose endpoint with titration and attrition; cannot become per-dose Cmax.
  • Japanese population and low-dose calibration limit extrapolation; other products/populations need not match.

Estimate survodutide-source-estimate-2026-10 · version 1

Common questions

Is survodutide the same as tirzepatide?

No. Survodutide targets GLP-1 and glucagon receptors; tirzepatide targets GLP-1 and GIP.

Does a liver-fat improvement mean cirrhosis is cured?

No. Liver fat, inflammation, scarring and clinical outcomes are different measures.

Sources Labels, studies and notes behind this guide

Catalog evidence: Human clinical trials. This describes the type of evidence, not a clinical review of every claim.

Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.

Notes on the quick facts

Why people look it up
Two related goals, measured with different endpoints.
Drug approach
Different from tirzepatide’s GLP-1/GIP pairing.
Time scale
The studies are not short cutting cycles.
Related compounds and examples

Related compounds

Mazdutide

Mazdutide is a weekly weight-management drug that also has a type 2 diabetes indication in China. People comparing it with tirzepatide want to know about appetite, weight loss and tolerability; it targets a different combination of hormone receptors, so doses are not interchangeable.

Semaglutide Injection (Ozempic/Wegovy)

Semaglutide can reduce hunger and food intake, helping people lose weight. Wegovy injections are prescribed for weight management; Ozempic injections treat type 2 diabetes. Both are taken weekly, with gradual dose increases to help manage digestive side effects.

Semaglutide Oral (Rybelsus)

Oral semaglutide offers a daily tablet option for adults with type 2 diabetes who want to avoid injections. The morning routine matters: food, drink and other tablets affect absorption, and different semaglutide products cannot be compared milligram for milligram.

Comments

Loading comments…